Refractory septic shock: Who and how should we purify?

Minerva Anestesiologica

Volumn 81, Issue 5, 2015, Pages 475-477

  Donadello, K ^a,b   Taccone, F S ^a  

^a ERASME HOSPITAL   (Belgium)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; BACTERIUM LIPOPOLYSACCHARIDE; ENDOTOXIN; HYPERTENSIVE FACTOR; NORADRENALIN;

ACUTE LUNG INJURY; BACTERIAL INFECTION; BLOOD PURIFICATION; CENTRAL VENOUS PRESSURE; EDITORIAL; GRAM NEGATIVE INFECTION; HEMODYNAMICS; HEMOFILTRATION; HEMOPERFUSION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; ISCHEMIA; LIFE SUSTAINING TREATMENT; LUNG CIRCULATION; MEAN ARTERIAL PRESSURE; MULTIPLE ORGAN FAILURE; NONHUMAN; PLASMAPHERESIS; PURIFICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPSIS; SEPTIC SHOCK; SYSTEMIC VASCULAR RESISTANCE; SHOCK;

HUMANS; SHOCK; SHOCK, SEPTIC;

EID: 84929833723     PISSN: 03759393     EISSN: 18271596     Source Type: Journal    
DOI: None     Document Type: Editorial

References (16)

1. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S et al. The PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012;366:2055-64.
2. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013;39:165-228.
3. Vincent JL, Nelson DR, Williams MD. Is worsening multiple organ failure the cause of death in patients with severe sepsis? Crit Care Med 2011;39:1050-5.
4. Brown SM, Lanspa MJ, Jones JP, Kuttler KG, Mstat YL, Carlson R et al. Survival after shock requiring high-dose vasopressor therapy. Chest 2013;143:664-71.
5. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005;365:63-78.
6. Rimmelé T, Kellum JA. Clinical review: blood purification for sepsis. Crit Care 2011;15:205.
7. Zhou F, Peng Z, Murugan R and Kellum JA. Blood purification and mortality in sepsis: a meta-analysis of randomized trials. Crit Care Med 2013;41:2209-0.
8. Iba T, Nagaoka I, Yamada A, Nagayama M, Miki T. Effect of hemoperfusion using polymyxin B-immobilized fibers on acute lung injury in a rat sepsis model. Int Journal Med Sciences 2014;11:255-61.
9. Koami H, Sakamoto Y, Miyasho T, Itami T, Tamura J, Ishizuka T et al. The effects of polymyxin B-immobilized fiber hemoperfusion on respiratory impairment in endotoxemic pigs. J Nippon Med Sch 2014;81.
10. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A et al. Early use of polymyxin B hemoperfusion in abdominal septic shock. The EUPHAS Randomized Controlled Trial. JAMA 2009;301:2445-52.
11. Ronco C, Klein DJ. Polymyxin B hemoperfusion: a mechanistic perspective. Critical Care 2014;18:309.
12. Klein DJ, Foster D, Schorr CA, Kazempour K, Walker PM, Dellinger RP. The EUPHRATES trial (evaluating the use of polymyxin B hemoperfusion in a randomized controlled trial of adults treated for endotoxemia and septic shock): study protocol for a randomized controlled trial. Trials 2014;15:218.
13. Monti G, Terzi V, Calini A, Di Marco F, Cruz D, Pulici M et al. Rescue therapy with polymyxin B hemoperfusion in high-dose vasopressor therapy refractory septic shock. Minerva Anestesiologica 2015;81:516-25.
14. Benbenishty J, Weissman C, Sprung CL, Brodsky-Israeli M, Weiss Y. Characteristics of patients receiving vasopressors. Heart & Lung 2010;40:247-52.
15. Asfar P, Meziani F, Hamel JF, Grelon F, Megarbane B, Anguel N et al. High versus low blood-pressure target in patients with septic shock. N Engl J Med 2014;370:1583-93.
16. Maynar J, Martínez-Sagasti F, Herrera-Gutiérrez M, Martí F, Candel FJ, Belda J et al. Direct hemoperfusion with polymyxin B-immobilized cartridge in severe sepsis due to intestinal perforation: hemodynamic findings and clinical considerations in anticoagulation therapy. Rev Esp Quimioter 2013;26:151-8.